These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29464559)

  • 1. Monoamine Oxidases.
    Edmondson DE; Binda C
    Subcell Biochem; 2018; 87():117-139. PubMed ID: 29464559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The structure of monoamine oxidases: past, present, and future.
    Iacovino LG; Magnani F; Binda C
    J Neural Transm (Vienna); 2018 Nov; 125(11):1567-1579. PubMed ID: 30167931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.
    Duarte P; Cuadrado A; León R
    Handb Exp Pharmacol; 2021; 264():229-259. PubMed ID: 32852645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor design for monoamine oxidases.
    Ramsay RR
    Curr Pharm Des; 2013; 19(14):2529-39. PubMed ID: 23116392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.
    Binda C; Hubálek F; Li M; Herzig Y; Sterling J; Edmondson DE; Mattevi A
    J Med Chem; 2005 Dec; 48(26):8148-54. PubMed ID: 16366596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
    Park HR; Kim J; Kim T; Jo S; Yeom M; Moon B; Choo IH; Lee J; Lim EJ; Park KD; Min SJ; Nam G; Keum G; Lee CJ; Choo H
    Bioorg Med Chem; 2013 Sep; 21(17):5480-7. PubMed ID: 23810676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.
    Binda C; Milczek EM; Bonivento D; Wang J; Mattevi A; Edmondson DE
    Curr Top Med Chem; 2011 Nov; 11(22):2788-96. PubMed ID: 22039878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives.
    Legoabe LJ; Petzer A; Petzer JP
    Eur J Med Chem; 2012 Mar; 49():343-53. PubMed ID: 22309913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Computer modelling of monoaminoxidases].
    Veselovsky AV; Ivanov AS; Medvedev AE
    Biomed Khim; 2015; 61(2):265-71. PubMed ID: 25978392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders.
    Binda C; Newton-Vinson P; Hubálek F; Edmondson DE; Mattevi A
    Nat Struct Biol; 2002 Jan; 9(1):22-6. PubMed ID: 11753429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 'gating' residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition.
    Milczek EM; Binda C; Rovida S; Mattevi A; Edmondson DE
    FEBS J; 2011 Dec; 278(24):4860-9. PubMed ID: 21978362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures.
    Binda C; Li M; Hubalek F; Restelli N; Edmondson DE; Mattevi A
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9750-5. PubMed ID: 12913124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study.
    Tandarić T; Prah A; Stare J; Mavri J; Vianello R
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32858935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of the human mitochondrial monoamine oxidase B: new chemical implications for neuroprotectant drug design.
    Binda C; Hubálek F; Li M; Castagnoli N; Edmondson DE; Mattevi A
    Neurology; 2006 Oct; 67(7 Suppl 2):S5-7. PubMed ID: 17030739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular aspects of monoamine oxidase B.
    Ramsay RR
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():81-9. PubMed ID: 26891670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design and analysis of MAO-B inhibitors for Parkinson's disease: using in silico approaches.
    Kare P; Bhat J; Sobhia ME
    Mol Divers; 2013 Feb; 17(1):111-22. PubMed ID: 23325357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties.
    Yelekçi K; Karahan O; Toprakçi M
    J Neural Transm (Vienna); 2007; 114(6):725-32. PubMed ID: 17401533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.
    Chung JY; Lee JW; Ryu CH; Min HK; Yoon YJ; Lim MJ; Park CH
    J Neurosci Res; 2015 Aug; 93(8):1267-78. PubMed ID: 25711470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.